share_log

Seelos Therapeutics | 10-Q: Q1 2024 Earnings Report

Seelos Therapeutics | 10-Q: Q1 2024 Earnings Report

Seelos Therapeutics | 10-Q：2024財年一季報
美股SEC公告 ·  05/14 08:04

Moomoo AI 已提取核心訊息

Seelos Therapeutics, Inc. reported a challenging financial quarter ending March 31, 2024, with a decrease in cash from $2.996 million to $524,000. The company's total assets also declined from $5.418 million to $3.612 million. Operating expenses saw a reduction, with research and development costs dropping from $5.668 million to $3.525 million, and general and administrative expenses from $4.072 million to $3.109 million. The net loss for the quarter was $2.664 million, an improvement from the previous year's $13.431 million. The company's future plans include focusing resources on the Phase II study of SLS-002 for acute suicidal ideation and behavior in major depressive disorder patients and the fully enrolled Phase II/III study of SLS-005 in ALS. Seelos also announced a strategic focus on mental health initiatives and a workforce reduction affecting 33% of its employees to reduce operating expenses and extend cash runway. The company faces challenges with maintaining NASDAQ listing requirements, with a recent notice indicating potential delisting due to non-compliance with the minimum bid price requirement and market value of listed securities rule.
Seelos Therapeutics, Inc. reported a challenging financial quarter ending March 31, 2024, with a decrease in cash from $2.996 million to $524,000. The company's total assets also declined from $5.418 million to $3.612 million. Operating expenses saw a reduction, with research and development costs dropping from $5.668 million to $3.525 million, and general and administrative expenses from $4.072 million to $3.109 million. The net loss for the quarter was $2.664 million, an improvement from the previous year's $13.431 million. The company's future plans include focusing resources on the Phase II study of SLS-002 for acute suicidal ideation and behavior in major depressive disorder patients and the fully enrolled Phase II/III study of SLS-005 in ALS. Seelos also announced a strategic focus on mental health initiatives and a workforce reduction affecting 33% of its employees to reduce operating expenses and extend cash runway. The company faces challenges with maintaining NASDAQ listing requirements, with a recent notice indicating potential delisting due to non-compliance with the minimum bid price requirement and market value of listed securities rule.
Seelos Therapeutics, Inc.報告顯示，2024年3月31日結束的財務季度面臨挑戰，現金從299.6萬美元下降至52.4萬美元。公司的總資產也從541.8萬美元下降至361.2萬美元。營業費用有所減少，研發成本從566.8萬美元降至352.5萬美元，一般和管理費用從407.2萬美元降至310.9萬美元。該季度淨虧損爲266.4萬美元，相較於去年的1343.1萬美元有所改善。公司未來計劃將資源集中在臨床二期研究SLS-002，用於治療大抑鬱症患者的急性自殺傾向和行爲，以及在ALS中已招募完畢的SLS-005的臨床二/三期研究上。Seelos還宣佈戰略重點放在心理健康項目上，並縮減33%的員工以減少營業費用並延長現金路徑。該公司面臨着維持納斯達克上市的挑戰，最近一則通知表明，由於未遵守最低買盤價格要求和已上市證券市值規則，可能面臨退市風險。
Seelos Therapeutics, Inc.報告顯示，2024年3月31日結束的財務季度面臨挑戰，現金從299.6萬美元下降至52.4萬美元。公司的總資產也從541.8萬美元下降至361.2萬美元。營業費用有所減少，研發成本從566.8萬美元降至352.5萬美元，一般和管理費用從407.2萬美元降至310.9萬美元。該季度淨虧損爲266.4萬美元，相較於去年的1343.1萬美元有所改善。公司未來計劃將資源集中在臨床二期研究SLS-002，用於治療大抑鬱症患者的急性自殺傾向和行爲，以及在ALS中已招募完畢的SLS-005的臨床二/三期研究上。Seelos還宣佈戰略重點放在心理健康項目上，並縮減33%的員工以減少營業費用並延長現金路徑。該公司面臨着維持納斯達克上市的挑戰，最近一則通知表明，由於未遵守最低買盤價格要求和已上市證券市值規則，可能面臨退市風險。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間